Biomira Inc.
Edmonton Research Park
2011 94th Street
Edmonton
Alberta
T6N 1H1
Canada
Tel: 780-450-3761
Fax: 780-463-0871
Website: http://www.biomira.com/
Email: ir@biomira.com
59 articles about Biomira Inc.
-
Biomira Inc. Shareholders Approve Move to U.S.
12/4/2007
-
Biomira Inc. Receives Nasdaq Delisting Notification
11/5/2007
-
Biomira Inc. Announces Third Quarter 2007 Financial Results
11/1/2007
-
Biomira Inc. Announces Date for Special Meeting of Shareholders
11/1/2007
-
New Data May Help Guide the Clinical Development of Biomira Inc.'s PX-478 and PX-866
10/24/2007
-
Biomira Inc. to Present at the Biotechnology Industry Organization (BIO) InvestorForum 2007
10/3/2007
-
Biomira Inc. Announces Plan to Change Name to Oncothyreon
9/28/2007
-
Canada's Biomira Inc. to Migrate to United States
9/12/2007
-
Biomira Inc. Stimuvax(R) Phase II Data Highlight Three-Year Survival Results for Patients with Non-Small Cell Lung Cancer
9/5/2007
-
Biomira Inc. initiates Phase 1 Trial of PX-478 in Patients with Advanced Metastatic Cancers
8/28/2007
-
Biomira Inc. and Merck KGaA Amend Cancer Vaccine Pact
8/8/2007
-
Biomira Inc. Announces Second Quarter 2007 Financial Results
8/2/2007
-
Biomira Inc. Appoints Industry Veteran as Chief Operating Officer
7/17/2007
-
Biomira Inc. Files Investigational New Drug Application for PX-478, A Novel Inhibitor of Hypoxia-Inducible Factor-1 Alpha
7/3/2007
-
Biomira Inc. to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
5/8/2007
-
Biomira Inc. Announces First Quarter 2007 Results
4/27/2007
-
Biomira Inc. Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at American Association for Cancer Research
4/16/2007
-
Biomira Inc. Reports Full Year and Fourth Quarter 2006 Financial Results
3/9/2007
-
Biomira Inc. to Present at Two Upcoming Investor Conferences
3/7/2007
-
Biomira Inc. Restates U.S. GAAP Note Disclosure for Non-Cash Charges
3/2/2007